These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 29108869)
1. The CADMUS trial - Multi-parametric ultrasound targeted biopsies compared to multi-parametric MRI targeted biopsies in the diagnosis of clinically significant prostate cancer. Grey A; Scott R; Charman S; van der Meulen J; Frinking P; Acher P; Liyanage S; Madaan S; Constantinescu G; Shah B; Graves CB; Freeman A; Jameson C; Ramachandran N; Emberton M; Arya M; Ahmed HU Contemp Clin Trials; 2018 Mar; 66():86-92. PubMed ID: 29108869 [TBL] [Abstract][Full Text] [Related]
2. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065 [TBL] [Abstract][Full Text] [Related]
3. Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study. Grey ADR; Scott R; Shah B; Acher P; Liyanage S; Pavlou M; Omar R; Chinegwundoh F; Patki P; Shah TT; Hamid S; Ghei M; Gilbert K; Campbell D; Brew-Graves C; Arumainayagam N; Chapman A; McLeavy L; Karatziou A; Alsaadi Z; Collins T; Freeman A; Eldred-Evans D; Bertoncelli-Tanaka M; Tam H; Ramachandran N; Madaan S; Winkler M; Arya M; Emberton M; Ahmed HU Lancet Oncol; 2022 Mar; 23(3):428-438. PubMed ID: 35240084 [TBL] [Abstract][Full Text] [Related]
4. Systematic and MRI-Cognitive Targeted Transperineal Prostate Biopsy Accuracy in Detecting Clinically Significant Prostate Cancer after Previous Negative Biopsy and Persisting Suspicion of Malignancy. Vėželis A; Platkevičius G; Kinčius M; Gumbys L; Naruševičiūtė I; Briedienė R; Petroška D; Ulys A; Jankevičius F Medicina (Kaunas); 2021 Jan; 57(1):. PubMed ID: 33435132 [No Abstract] [Full Text] [Related]
5. An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience. Costa DN; Kay FU; Pedrosa I; Kolski L; Lotan Y; Roehrborn CG; Hornberger B; Xi Y; Francis F; Rofsky NM Urol Oncol; 2017 Apr; 35(4):149.e15-149.e21. PubMed ID: 27939349 [TBL] [Abstract][Full Text] [Related]
6. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy. Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233 [TBL] [Abstract][Full Text] [Related]
7. 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies. Piert M; Montgomery J; Kunju LP; Siddiqui J; Rogers V; Rajendiran T; Johnson TD; Shao X; Davenport MS J Nucl Med; 2016 Jul; 57(7):1065-70. PubMed ID: 26985061 [TBL] [Abstract][Full Text] [Related]
8. The prostate cancer detection rates of CEUS-targeted versus MRI-targeted versus systematic TRUS-guided biopsies in biopsy-naïve men: a prospective, comparative clinical trial using the same patients. Postema AW; Scheltema MJ; Mannaerts CK; Van Sloun RJ; Idzenga T; Mischi M; Engelbrecht MR; De la Rosette JJ; Wijkstra H BMC Urol; 2017 Apr; 17(1):27. PubMed ID: 28381220 [TBL] [Abstract][Full Text] [Related]
9. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans. Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990 [TBL] [Abstract][Full Text] [Related]
10. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. Wegelin O; Exterkate L; van der Leest M; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; Barentsz JO; Somford DM; van Melick HHE Eur Urol; 2019 Apr; 75(4):582-590. PubMed ID: 30522912 [TBL] [Abstract][Full Text] [Related]
11. Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer. Panebianco V; Valerio MC; Giuliani A; Pecoraro M; Ceravolo I; Barchetti G; Catalano C; Padhani AR Eur Urol Oncol; 2018 Aug; 1(3):208-214. PubMed ID: 31102623 [TBL] [Abstract][Full Text] [Related]
12. The PICTURE study -- prostate imaging (multi-parametric MRI and Prostate HistoScanning™) compared to transperineal ultrasound guided biopsy for significant prostate cancer risk evaluation. Simmons LA; Ahmed HU; Moore CM; Punwani S; Freeman A; Hu Y; Barratt D; Charman SC; Van der Meulen J; Emberton M Contemp Clin Trials; 2014 Jan; 37(1):69-83. PubMed ID: 24291455 [TBL] [Abstract][Full Text] [Related]
13. The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification. Hamid S; Donaldson IA; Hu Y; Rodell R; Villarini B; Bonmati E; Tranter P; Punwani S; Sidhu HS; Willis S; van der Meulen J; Hawkes D; McCartan N; Potyka I; Williams NR; Brew-Graves C; Freeman A; Moore CM; Barratt D; Emberton M; Ahmed HU Eur Urol; 2019 May; 75(5):733-740. PubMed ID: 30527787 [TBL] [Abstract][Full Text] [Related]
14. Multiparametric MRI in men with clinical suspicion of prostate cancer undergoing repeat biopsy: a prospective comparison with clinical findings and histopathology. Boesen L; Nørgaard N; Løgager V; Balslev I; Thomsen HS Acta Radiol; 2018 Mar; 59(3):371-380. PubMed ID: 28679325 [TBL] [Abstract][Full Text] [Related]
15. Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging. Chaloupka M; Bischoff R; Pfitzinger P; Lellig E; Ledderose S; Buchner A; Schlenker B; Stief C; Clevert DA; Apfelbeck M Clin Hemorheol Microcirc; 2019; 73(1):105-111. PubMed ID: 31561351 [TBL] [Abstract][Full Text] [Related]
16. Evolution of Targeted Prostate Biopsy by Adding Micro-Ultrasound to the Magnetic Resonance Imaging Pathway. Wiemer L; Hollenbach M; Heckmann R; Kittner B; Plage H; Reimann M; Asbach P; Friedersdorff F; Schlomm T; Hofbauer S; Cash H Eur Urol Focus; 2021 Nov; 7(6):1292-1299. PubMed ID: 32654967 [TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance imaging-transrectal ultrasound image fusion guidance of prostate biopsies: current status, challenges and future perspectives. Boesen L Scand J Urol; 2019; 53(2-3):89-96. PubMed ID: 31006323 [TBL] [Abstract][Full Text] [Related]
18. First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography-guided biopsies for the diagnosis of localised prostate cancer. Mozer P; Rouprêt M; Le Cossec C; Granger B; Comperat E; de Gorski A; Cussenot O; Renard-Penna R BJU Int; 2015 Jan; 115(1):50-7. PubMed ID: 24552477 [TBL] [Abstract][Full Text] [Related]
19. A Prospective Comparison of Selective Multiparametric Magnetic Resonance Imaging Fusion-Targeted and Systematic Transrectal Ultrasound-Guided Biopsies for Detecting Prostate Cancer in Men Undergoing Repeated Biopsies. Boesen L; Nørgaard N; Løgager V; Balslev I; Thomsen HS Urol Int; 2017; 99(4):384-391. PubMed ID: 28651247 [TBL] [Abstract][Full Text] [Related]
20. Detection of clinically significant prostate cancer in biopsy-naïve men: direct comparison of systematic biopsy, multiparametric MRI- and contrast-ultrasound-dispersion imaging-targeted biopsy. Mannaerts CK; Engelbrecht MRW; Postema AW; van Kollenburg RAA; Hoeks CMA; Savci-Heijink CD; Van Sloun RJG; Wildeboer RR; De Reijke TM; Mischi M; Wijkstra H BJU Int; 2020 Oct; 126(4):481-493. PubMed ID: 32315112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]